Journal article
Standardized Expression of 18F-NAV4694 and 11C-PiB b-amyloid PET results with the centiloid scale
CC Rowe, G Jones, V Dore, S Pejoska, L Margison, RS Mulligan, J Gordon Chan, K Young, VL Villemagne
Journal of Nuclear Medicine | SOC NUCLEAR MEDICINE INC | Published : 2016
Abstract
A common quantitative output value for PET measures of β-amyloid (Aâ) binding across tracers and methods would allow better comparison of data across sites and application of universal diagnostic and prognostic values. A method has recently been developed that generates a unit of measurement called the centiloid. We applied this method to 2-[2-18F-fluoro-6-(methylamino)-3-pyridinyl]-1-benzofuran-5-ol (18F-NAV4694) and 11C-Pittsburgh compound B (11C-PiB) Aβ images to derive the scaling factor required to express tracer binding in centiloids. Methods: Fifty-five participants, including 10 young controls (33 ± 7 y old), underwent both 11C-PiB and 18F-NAV4694 imaging no more than 3 mo apart, wit..
View full abstractGrants
Awarded by National Health Medical Research Council (NHMRC) of Australia
Awarded by National Health and Medical Research Council of Australia
Funding Acknowledgements
The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. Cristopher Rowe has received research grants for imaging in dementia from Bayer-Schering Pharma, Avid Radiopharmaceuticals, GE Healthcare, Piramal, Astra Zeneca, and Navidea. He has been a consultant or paid speaker at sponsored conference sessions for Bayer-Schering Pharma, Piramal, GE Healthcare, Astra Zeneca, Roche, and Janssen. Victor Villemagne has been a consultant or paid speaker at sponsored conference sessions for Bayer-Schering Pharma, Piramal, GE Healthcare, Astra Zeneca, and Novartis. The study was partially supported by grants 1044361 and 1071430 from the National Health Medical Research Council (NHMRC) of Australia and by a research grant for imaging in dementia from Navidea. The funding sources had no input into the design or conduct of the study; the collection, management, analysis, or interpretation of the data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. No other potential conflict of interest relevant to this article was reported.